

April 13, 2026

Company Name: **Veritas In Silico Inc.**
Representative: **Shingo NAKAMURA**,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact Person: **Tsuneo GODA**,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

Termination of Collaborative Drug Discovery Research with Takeda on mRNA-Targeted Small-Molecule Drugs

Veritas In Silico Inc. (“VIS”) has been conducting a collaborative drug discovery research on mRNA-targeted small-molecule drugs (“the Research”) with Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; President & CEO: Christophe Weber; “Takeda”) under “COLLABORATIVE RESEARCH AND LICENSE AGREEMENT” entered into with on June 19, 2023. While the Research had yielded certain results to date, following discussions with Takeda and VIS, the Research shall be terminated amicably effective on April 13, 2026.

Going forward, they are to continue to discuss and consider possible future applications of the findings gained through the Research.

● Impact on Future Business Performance of VIS

The impact of the termination of the Research on VIS’s business performance is expected to be limited, and no change is anticipated to the earnings forecast for the fiscal year ending December 2026, announced on February 15, 2026.

In case any matters requiring disclosure arise in the future, they will be promptly disclosed.

END